Human Cytomegalovirus Inhibitor AL18 Also Possesses Activity against Influenza A and B Viruses

Citation for published version:

Digital Object Identifier (DOI):
10.1128/AAC.01219-12

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Antimicrobial Agents and Chemotherapy

Publisher Rights Statement:
Copyright © 2012, American Society for Microbiology. All Rights Reserved.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Human Cytomegalovirus Inhibitor AL18 Also Possesses Activity against Influenza A and B Viruses

Giulia Muratore,a Beatrice Mercorelli,a Laura Goracci,b Gabriele Cruciani,b Paul Digard,c Giorgio Palù,a and Arianna Loregiana
Department of Molecular Medicine, University of Padua, Padua, Italya; Department of Chemistry, University of Perugia, Perugia, Italyb; and Roslin Institute, University of Edinburgh, Easter Bush, Midlothian, United Kingdomc

AL18, an inhibitor of human cytomegalovirus DNA polymerase, was serendipitously found to also block the interaction between the PB1 and PA polymerase subunits of influenza A virus. Furthermore, AL18 effectively inhibited influenza A virus polymerase activity and the overall replication of influenza A and B viruses. A molecular model to explain the binding of AL18 to both cytomegalovirus and influenza targets is proposed. Thus, AL18 represents an interesting lead for the development of new antivirals.

Influenza A virus is a major human pathogen responsible for respiratory diseases characterized by high morbidity and significant mortality. Influenza A causes seasonal epidemics affecting millions of people worldwide but can also provoke pandemic outbreaks with higher attack rates and potentially more-severe disease (18).

Currently, two classes of anti-influenza A drugs are available: adamantanes, which block the M2 ion channel and inhibit virus entry, and neuraminidase inhibitors, which prevent the release of virions from the host cell (5). However, they all suffer from limited efficacy, adverse side effects, and emergence of drug resistance. Vaccines also exist, but they must be reformulated annually and they give limited protection. Thus, there is still a considerable need for new anti-influenza drugs.

The influenza A RNA polymerase, a heterotrimer of the PA, PB1, and PB2 subunits, provides an underexploited drug target. The three subunits bind each other and are all essential for viral RNA synthesis (18). Recent crystal structures revealed that the PA-PB1 binding interface consists of an N-terminal helix from PB1 that binds into a groove in the C terminus of PA (7, 17). Since the association of these subunits is essential for viral replication (19), and since the amino acids of both PB1 and PA that are crucial for subunit interaction are highly conserved among influenza A strains (6, 10), this interaction represents an attractive target for antiviral drugs. To this end, we recently developed a PA-PB1 interaction assay and used it to identify compounds able to inhibit the interaction (16).

In these influenza A PB1-PA binding assays, microtiter wells coated with 6His-PA239-716, a 6His-tagged form of the PA C-terminal domain, are incubated with glutathione S-transferase (GST)-PB11-25, a GST fusion with the N-terminal 25 residues of PB1 (which are sufficient to bind the PA C-terminal domain [6, 7]), in the absence or the presence of test compounds. Active inhibitors, such as a PB1-derived peptide fused to sequences from HIV Tat (PB11-15-Tat [6]) or the small-molecule “compound 1” inhibitor we recently identified (16), effectively blocked the PA-PB1 interaction as expected (Fig. 1). During the course of these studies, we also tested small molecules able to disrupt the interaction between the UL54 and UL44 subunits of human cytomega-
lovirus (HCMV) DNA polymerase (13), expecting them to provide negative controls. Unexpectedly, the most active of the HCMV inhibitors, AL18, also inhibited the PA-PB1 interaction with a 50% inhibitory concentration (IC50; calculated by linear regression using the computer program GraphPad Prism version 4.0) of 20.3 ± 2.6 μM (Fig. 1). In contrast, another of the previously characterized UL54-UL44 inhibitors, AL5 (13), did not affect PA-PB1 binding (Fig. 1).

To investigate whether the in vitro inhibitory activity of AL18 on the minimal PA-PB1 binding domains was matched by a corresponding effect on the influenza A transcription machinery in cells, the compound was tested in influenza A minireplicon assays (15, 16). Ribavirin (RBV; from Roche), a known inhibitor of viral RNA polymerases (20), and the anti-PA-PB1 compound 1 served as positive controls. Human embryonic kidney (HEK) 293T cells were cotransfected with plasmids encoding the three polymerase subunits and the viral nucleoprotein (NP) along with a plasmid carrying the firefly luciferase reporter gene flanked by the noncoding sequences of influenza A segment 8 and treated with the indicated compounds. The transfection mixtures also contained a plasmid constitutively expressing Renilla luciferase which served to normalize variations in transfection efficiency. Luciferase activity was quantified at 24 h posttransfection. The data are the means ± SDs of three independent experiments plotted relative to the activity seen in the presence of the compound vehicle (dimethyl sulfoxide [DMSO]). Omission of PB2 served as a negative control.

FIG 2 Ability of AL18 to inhibit influenza A polymerase activity in minireplicon assays. HEK 293T cells were cotransfected with plasmids encoding PB1, PB2, PA, and NP along with a plasmid carrying the firefly luciferase reporter gene flanked by the noncoding sequences of influenza A segment 8 and treated with the indicated compounds. The transfection mixtures also contained a plasmid constitutively expressing Renilla luciferase which served to normalize variations in transfection efficiency. Luciferase activity was quantified at 24 h posttransfection. The data are the means ± SDs of three independent experiments plotted relative to the activity seen in the presence of the compound vehicle (dimethyl sulfoxide [DMSO]). Omission of PB2 served as a negative control.

FIG 3 Activity of AL18 against influenza A replication. (A) Effects of the indicated compounds on plaque formation by A/PR/8/34 virus in MDCK cells. Representative pictures of mock-infected (−PR8), A/PR/8/34-infected untreated (+ PR8/−AL18), and A/PR/8/34-infected, AL18-treated (+ PR8/+AL18) cells are shown on the right. (B) Effects of AL18 (left) and of RBV as a control (right) on the yield of A/PR/8/34 virus following low-MOI infections of MDCK cells, determined at 12, 24, and 48 h p.i. (C) Inhibition of A/PR/8/34 virus replication by AL18 and by compound 1 added at different times before or during the viral life cycle. Data shown in panels A, B, and C are the means ± SDs of two or three independent experiments in duplicate.
TABLE 1 Activity of AL18 against a panel of DNA and RNA viruses

<table>
<thead>
<tr>
<th>Virus (strain)</th>
<th>Family (subfamily)</th>
<th>Genome</th>
<th>Activity of:</th>
<th>Controlb</th>
<th>Activity of:</th>
<th>Controlb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>EC50 (μM)</td>
<td>MTT assay</td>
<td>CC50 (μM)</td>
<td>SI</td>
</tr>
<tr>
<td>HSV-1 (F)</td>
<td>Herpesviridae (α)</td>
<td>dsDNA</td>
<td>&gt;30</td>
<td>&gt;250</td>
<td>&gt;5</td>
<td>1.6 ± 0.7</td>
</tr>
<tr>
<td>HCMV (AD169)</td>
<td>Herpesviridae (β)</td>
<td>dsDNA</td>
<td>0.9 ± 0.2</td>
<td>250 ± 58</td>
<td>232 ± 24</td>
<td>278</td>
</tr>
<tr>
<td>HHV-6A (GS)</td>
<td>Herpesviridae (β)</td>
<td>dsDNA</td>
<td>5.8 ± 1.2</td>
<td>22.4 ± 4.8</td>
<td>6.1 ± 2.5</td>
<td>770 ± 132</td>
</tr>
<tr>
<td>HHV-6B (Z29)</td>
<td>Herpesviridae (β)</td>
<td>dsDNA</td>
<td>1.1 ± 1.2</td>
<td>3.7</td>
<td>7.3 ± 1.9</td>
<td>980 ± 144</td>
</tr>
<tr>
<td>MCMV (Smith)</td>
<td>Herpesviridae (β)</td>
<td>dsDNA</td>
<td>&gt;30</td>
<td>&gt;100</td>
<td>&gt;3</td>
<td>0.7 ± 0.2</td>
</tr>
<tr>
<td>HHV-8</td>
<td>Herpesviridae (γ)</td>
<td>dsDNA</td>
<td>&gt;50</td>
<td>&gt;250</td>
<td>&gt;5</td>
<td>5.8 ± 1.3</td>
</tr>
<tr>
<td>AdV</td>
<td>Adenoviridae</td>
<td>dsDNA</td>
<td>&gt;50</td>
<td>&gt;250</td>
<td>&gt;5</td>
<td>25.6 ± 3.2</td>
</tr>
<tr>
<td>Influenza A (A/PR/8/34)</td>
<td>Orthomyxoviridae</td>
<td>ssRNA</td>
<td>14.5 ± 2.1</td>
<td>&gt;250</td>
<td>&gt;250</td>
<td>&gt;17</td>
</tr>
<tr>
<td>Influenza B (B/Lee/40)</td>
<td>Orthomyxoviridae</td>
<td>ssRNA</td>
<td>8.3 ± 1.9</td>
<td>&gt;250</td>
<td>&gt;250</td>
<td>&gt;30</td>
</tr>
<tr>
<td>MV</td>
<td>Paramyxoviridae</td>
<td>ssRNA</td>
<td>&gt;50</td>
<td>&gt;250</td>
<td>&gt;5</td>
<td>85.4 ± 5.8</td>
</tr>
<tr>
<td>RSV</td>
<td>Paramyxoviridae</td>
<td>ssRNA</td>
<td>&gt;50</td>
<td>&gt;250</td>
<td>&gt;5</td>
<td>21.6 ± 3.6</td>
</tr>
<tr>
<td>VSV</td>
<td>Rhabdoviridae</td>
<td>ssRNA</td>
<td>&gt;50</td>
<td>&gt;250</td>
<td>&gt;5</td>
<td>10.3 ± 2.9</td>
</tr>
<tr>
<td>COX B1</td>
<td>Picornaviridae</td>
<td>ssRNA</td>
<td>&gt;50</td>
<td>&gt;250</td>
<td>&gt;5</td>
<td>5 ND</td>
</tr>
</tbody>
</table>

a dsDNA, double-stranded DNA; ND, not determined; ssRNA, single-stranded RNA.
b Control compounds were GCV for HSV-1, HCMV, and HHV-8, FOS for HHV-6A and HHV-6B, CDV for MCMV and AdV, and RBV for all RNA viruses except COX B1.

c EC50, the concentration of compound that inhibits 50% of virus replication, was determined by PRAs for HCMV, HSV-1, MCMV, AdV, influenza A, influenza B, MV, RSV, and VSV, by quantitative real-time PCR for HHV-6 and HHV-8, and by estimation of cytopathic effect for COX B1.
d CC50, the concentration of compound that inhibits 50% of cell growth, was determined in different cell lines by MTT assays and by ATP assays and was calculated by linear regression using GraphPad Prism 4.0. Cell lines were Vero for HSV-1, MV, and COX B1, HFF for HCMV, HSB-2 for HHV-6A, MOLT-3 for HHV-6B, NIH 3T3 for MCMV, BE-3 for HHV-8, AS49 for AdV, MDCK for influenza A and influenza B, I.929 for VSV, and HEp-2 for RSV.
e SI, the selectivity index as determined by the ratio between the CC50 determined by MTT assays and the EC50. CC50 and EC50 were determined under the same cell culture conditions.

The antiviral drugs ganciclovir (GCV; from Sigma), foscarnet (Pharmacia, Uppsala, Sweden), oseltamivir (Roche), oseltamivir-resistant neuraminidase (from H1 or H3 subtypes of influenza A), and valacyclovir (from Neos, San Diego, CA) were used as controls.

Antiviral with Anti-HCMV and Anti-Influenza Activity

The antiviral drugs ganciclovir (GCV; from Sigma), foscarnet (Pharmacia, Uppsala, Sweden), oseltamivir (Roche), oseltamivir-resistant neuraminidase (from H1 or H3 subtypes of influenza A), and valacyclovir (from Neos, San Diego, CA) were used as controls.

Next, the effect of AL18 on the replication of influenza A (A/PR/8/34 strain, from the Department of Pathology, University of Cambridge, United Kingdom) in Madin-Darby canine kidney (MDCK) cells was evaluated by plaque reduction assays (PRAs) as described previously. (16) AL18 inhibited influenza A plaque formation in a dose-dependent manner (Fig. 3A), with EC50s similar to those of compound 1 (EC50s were 14.5 ± 2.1 μM and 19.4 ± 3.2 μM, respectively) (Fig. 3A and Table 1), while AL5 did not show any significant activity (EC50 > 100 μM) (Fig. 3A).

In addition, AL18 showed antiviral activity against several influenza A strains, including pandemic swine-originated influenza virus strains (from C. Salata, University of Padua, Italy) and an oseltamivir-resistant clinical isolate (A/Parma/24/09; from I. Donatelli, Istituto Superiore di Sanità, Rome, Italy), with EC50s ranging from 13.5 to 27.8 μM. In parallel, we tested the cytotoxicity of the compound both by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma) assays (16) and by using a bioluminescence-based ATP determination kit (ATPlite; PerkinElmer). AL18 did not exhibit cytotoxicity in MDCK cells up to at least 250 μM (Table 1). We also tested the activity of AL18 on viral yield. MDCK cells were infected with A/PR/8/34 at a multiplicity of infection (MOI) of 0.01 and then treated with AL18 or RBV as a control, and the viral titers in compound-treated and control cells were measured at 12, 24, and 48 h post-infection (p.i.). AL18 inhibited virus yield with an EC50 of 2.5 ± 0.9 μM at 12 h, an EC50 of 4.5 ± 1.5 μM at 24 h, and an EC50 of 7.5 ± 2.6 μM at 48 h p.i. (Fig. 3B). As expected, RBV also effectively reduced viral titers (Fig. 3B). In time-of-addition experiments, performed as described in reference 9, inhibition was observed when AL18, or compound 1 for comparison, was added preinfection or up to 2 h postinfection but not at later time points (Fig. 3C). Thus, in contrast to M2 and neuraminidase inhibitors, which block virus replication at earlier and later stages, respectively (8, 21), both AL18 and compound 1 appear to act at early to middle stages, consistent with the observation of inhibition of the viral polymerase activity in minirepli-
con assays (Fig. 2).
(FOS; from Sigma), cidofovir (CDV; from Pfizer), and RBV were used as reference compounds.

As previously reported (13), AL18 showed potent antiviral activity against HCMV with a selectivity index (SI) comparable to that of GCV (Table 1). Conversely, it was inactive against other herpesviruses, such as HSV-1, HHV-8, or MCMV, but showed some inhibitory activity against HHV-6A and HHV-6B (Table 1). However, the latter activity may have been due in part to cytotoxicity in the cell lines used to grow the HHV-6 viruses, as the SI values were poor (Table 1). No significant antiviral activity was seen against another DNA virus (adenovirus) or RNA viruses other than influenza A and influenza B (Table 1). Remarkably, AL18 exhibited an EC50 against influenza B (8.3 \pm 1.9 \mu M) that was comparable to that against influenza A (Table 1). Thus, AL18 has dual specificity, acting as a potent inhibitor of one or more members from two evolutionarily distinct virus families: HCMV and influenza A and B.

The activity of AL18 against both HCMV DNA polymerase (13) and influenza A RNA polymerase was surprising and would not have been predicted on the basis of any obvious sequence similarity of the polymerase interaction domains. Indeed, the lack of specific antiviral activity of AL18 against herpesviruses other than HCMV was not completely unexpected. Previous studies have shown that the molecular details of the HCMV UL54-UL44 interaction are quite different from those of the interaction between the counterparts from other herpesviruses (1, 2, 4, 11, 12, 22). Nevertheless, knowing the predicted target sites of the drug in both systems allowed us to use molecular modeling to investigate whether a plausible explanation for the dual specificity was able to be found. In fact, by analyzing docked poses of AL18 with the UL44 protein of HCMV DNA polymerase and with the PA subunit of influenza A RNA polymerase (Fig. 4) using the FLAP (Fingerprints for Ligands And Proteins) software (3), possible molecular explanations for the dual anti-HCMV and anti-influenza activities of the compound were able to be proposed. According to the FLAP docking poses with HCMV UL44 (Fig. 4A), AL18 strongly interacts with three residues in the central part of the so-called “connector loop,” a region of UL44 shown to be crucial for UL54 binding (1, 12). In particular, the two anilinic groups of AL18 form hydrogen bonds with D134 and R137. Additionally, the side chain of I135 is positioned as a hydrophobic anchor underneath the hydrogen-bonding network of AL18, mimicking the behavior already observed for UL54 binding by UL44 (1). Furthermore, a second set of weaker hydrogen-bonding interactions might occur between the carbonyl and hydroxyl groups of AL18 at positions 10 and 4 and the T41 and T79 residues of UL44, respectively. Inspecting the top 10 docking solutions, eight out of 10 poses of AL18 in UL44 are in agreement with the binding mode reported in Fig. 4A. Compound 1 was reported to not inhibit HCMV replication (16). Nine out of the 10 best FLAP poses of compound 1 in UL44 (Fig. 4B) are located in a more external binding region (inset in Fig. 4B), and thus, being highly exposed at

![Molecular basis of the interaction of AL18 and compound 1 with the UL44 subunit of HCMV DNA polymerase and the PA subunit of influenza A RNA polymerase.](image-url)
the UL44 surface, compound 1 may be easily displaced. The only pose predicted at the same AL18 and UL54 binding regions is driven by hydrophobic interactions only, while H-bond interactions do not occur.

By analyzing FLAP docked poses with influenza A PA, AL18 (Fig. 4C) appears to be docked in the same binding region of compound 1 (Fig. 4D) in the PA cavity (16). Looking at the best 10 poses in terms of FLAP similarity scores, all of them display the same binding region. Seven poses out of 10 are oriented as reported in Fig. 4C. The aromatic moiety of AL18 is involved in a π-π stacking with W706. Furthermore, AL18 forms a hydrogen-bonding network with the N412, Q408, and K643 residues. All the mentioned AL18-interacting residues of PA are highly conserved among influenza A virus strains (6), suggesting that AL18 will likely have broad-spectrum activity against influenza A viruses of both human and animal origin. Intriguingly, these residues of influenza A PA are also conserved in influenza B and match well upon structural alignment (16). Thus, the FLAP docking pose is in agreement with the experimentally observed inhibition of both influenza A and influenza B replication by AL18. The remaining three poses of AL18 in influenza A PA overlap the other poses, but the structures are oppositely oriented, having the hydroxyl moiety pointed toward the N412 residue. Due to the specific structure of AL18, the hydrogen-bonding network, as well as the hydrophobic interaction with W706, is largely retained also in the second binding mode.

In contrast to AL18 and compound 1, AL5 docking into the influenza A PA cavity seems to be driven mainly by hydrophobic interactions involving the W706 residue (data not shown). All the best 10 poses for AL5 are perfectly matching. The lack of an H-bond network can be responsible for a weak interaction of AL5 with PA, which may explain the lack of anti-influenza activity of AL5. Mutagenesis studies to confirm the molecular modeling predictions are planned.

In conclusion, the AL18 compound exhibits anti-influenza A and anti-influenza B activity with a potency comparable to that of compound 1, a recently identified antiviral agent that acts by the same mechanism (16). Unlike compound 1, however, AL18 also possesses potent anti-HCMV activity. Thus, these data suggest that AL18 merits further consideration as a starting point for the development of new antiviral agents.

ACKNOWLEDGMENTS

We thank W. S. Barclay, R. Cusinato, I. Donatelli, D. Lembo, L. Naesens, and C. Salata for kindly providing viruses. We gratefully acknowledge Donald M. Coen for critical reading of the manuscript.

This work was supported by MURST EX60% and PRIN 2008 (grant no. 20085FF4J4 to A.L.), by the Italian Ministry of Health and Istituto Superiore Sanità, Progetto finalizzato 2009 “Studio e sviluppo di nuovi polimerasi di virus oncogenici e del l’immunossuppressione nelle infezioni da virus oncogenici e da virus del cancro.”

REFERENCES


